Acrivon Therapeutics, Inc. - Form 4 Filing

This filing details a transaction by Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. On July 21, 2026, Miller sold 573 shares of Common Stock at a price of $1.76 per share. This sale was automatically executed to cover tax withholdings upon the vesting of restricted stock units. Following this transaction, Miller holds 82,194 shares of Common Stock. The transaction was reported on Form 4, filed on July 23, 2026.